Kaye Edward M. MD 4

What Happened
Edward M. Kaye, MD, a director of Stoke Therapeutics (STOK), was granted a derivative award of 17,786 shares (transaction code A) on June 3, 2026. The reported acquisition price is $0.00, so there was no cash purchase or sale reported — this is a compensation grant (an option-style award per the filing footnote), not an open-market trade.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (appears timely; Form 4 is due within two business days).
• Transaction type/code: A = Award (derivative); amount: 17,786 shares; price: $0.00; reported value: $0.
• Shares owned after transaction: Not disclosed in the provided excerpt.
• Footnote: The option shall vest in full on the earlier of (i) June 3, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to Kaye’s continued service (per filing F1).
• No sale or cash exercise reported; no 10b5-1 plan or tax-withholding details provided in the excerpt.

Context
This is a typical director compensation grant (a derivative/option award) that vests in the future and does not represent an immediate purchase or sale of shares. Such awards are common for board members and do not by themselves indicate a buy/sell signal; they reflect compensation tied to continued service or time-based vesting.